Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.62 |
| ▸ | MET | P08581 | 1/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.57 |
| ▸ | ROS1 | P08922 | 1/20 | 0.57 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.55 |
| ▸ | INSR | P06213 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459614 | 0.91 | LRRK2 (0.55) | EGFRMETLRRK2ALKINSR | |
| SCHEMBL1460622 | 0.89 | LRRK2 (0.59) | EGFRMETLRRK2ALK | |
| SCHEMBL1459616 | 0.88 | EGFR (0.56) | EGFRMETLRRK2ALKROS1 | |
| SCHEMBL600864 | 0.87 | GLO1 (0.58) | EGFRMETLRRK2ALKROS1 | |
| SCHEMBL9911236 | 0.87 | EGFR (0.64) | EGFRMETLRRK2ALKROS1 | |
| Hydrochloric Acid SCHEMBL1707842 | 0.86 | EGFR (0.63) | EGFRMETLRRK2ALKROS1 | |
| SCHEMBL600894 | 0.85 | GLO1 (0.56) | EGFRMETLRRK2ALKROS1 | |
| SCHEMBL1039383 | 0.84 | MAPK9 (0.66) | EGFRMETALKROS1MAPK3 | |
| SCHEMBL10011055 | 0.84 | EGFR (0.61) | EGFRMETLRRK2ALKMAPK3 | |
| SCHEMBL1036294 | 0.83 | ALK (0.68) | EGFRMETLRRK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | claimed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | claimed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | claimed |
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | EGFR 834/4885MET 3979/4885LRRK2 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.